Featured Content
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Loss of 2q37 Linked to Immunomodulatory Drug Resistance in Multiple Myeloma
Source: Myeloma - Hematology Advisor Researchers sought to determine whether there was a connection between loss of the 2q37 chromosomal region and resistance to immunomodulatory drugs in MM. Read More
Risk of Infection Increases with Longer Duration of Bispecific Antibody Therapy in Multiple Myeloma
Source: Pharmacy Times articles Researchers also noted an increasing rate of seroconversion with COVID-19 booster vaccination series. Read More
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party
Source: Myeloma : nature.com subject feeds Post Content Read More
Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis
Source: Myeloma : nature.com subject feeds Post Content Read More
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Source: Myeloma - Hematology Advisor Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests. Read More
Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma
Source: Myeloma - Hematology Advisor Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests. Read More
Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness
Source: Myeloma : nature.com subject feeds Post Content Read More
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020
Source: Myeloma : nature.com subject feeds Post Content Read More
Cilta-Cel May Fulfill Unmet Need for Multiple Myeloma Patients in China
Source: Myeloma - Hematology Advisor Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers. Read More
Research Continues Evaluating Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
Source: Pharmacy Times articles Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies. Read More
Recent Publications
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma
Hematol Oncol. 2022 Nov 28. doi: 10.1002/hon.3102. Online ahead of print. ABSTRACT BACKGROUND CONTEXT: Multiple myeloma (MM) is a systemic disorder characterised by proliferation of B-lymphocytes and plasma cells in the bone marrow. The primary aims of the management...
Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Intern Med J. 2022 Nov 28. doi: 10.1111/imj.15980. Online ahead of print. ABSTRACT Waldenström Macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of IgM paraprotein, bone marrow infiltration by clonal small B lymphocytes with...
Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma
Ann Hematol. 2022 Nov 28. doi: 10.1007/s00277-022-05059-4. Online ahead of print. ABSTRACT The nutritional risk index (NRI), which is based on weight and albumin levels, is closely associated with the prognosis of many cancers. However, its prognostic value has not...
Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
Open Forum Infect Dis. 2022 Oct 31;9(11):ofac574. doi: 10.1093/ofid/ofac574. eCollection 2022 Nov. ABSTRACT BACKGROUND: Patients with multiple myeloma are at higher risk for infections due to disease pathogenesis and administered therapies. The purpose of this study...
Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
Front Oncol. 2022 Nov 10;12:1014904. doi: 10.3389/fonc.2022.1014904. eCollection 2022. ABSTRACT V-type immunoglobulin domain-containing suppressor of T cell activation (VISTA) is considered as an immunosuppressive factor and potential therapeutic target for anticancer...
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
Front Oncol. 2022 Nov 9;12:1038329. doi: 10.3389/fonc.2022.1038329. eCollection 2022. ABSTRACT Resistance to immunomodulatory drugs (IMiDs®) is a major cause of treatment failure, disease relapse and ultimately poorer outcomes in multiple myeloma (MM). In order to...
Expression of Inhibitory Molecules (Arginase-1, IDO, and PD-L1) by Myeloid-Derived Suppressor Cells in Multiple Myeloma Patients in Remission
Bull Exp Biol Med. 2022 Nov 28. doi: 10.1007/s10517-022-05651-8. Online ahead of print. ABSTRACT We studied suppressor potential of myeloid-derived suppressor cells (MDSC) in multiple myeloma patients, including before and after mobilization of hematopoietic stem...
TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma
BMC Res Notes. 2022 Nov 26;15(1):352. doi: 10.1186/s13104-022-06237-3. ABSTRACT OBJECTIVE: Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual...
